BioSpace News Archive

Accuray Incorporated announced the appointment of Robert C. Kill to the company’s Board of Directors, effective as of January 30, 2023.

McKesson Corporation (NYSE: MCK) has released its fiscal 2023 third-quarter financial results.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. ET.

Lannett Company, Inc. reported financial results for its fiscal 2023 second quarter ended December 31, 2022.

Guardant Health, Inc., a leading precision oncology company, announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 2,800 shares of G1’s common stock and 1,400 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Cullinan Oncology, Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 56,000 shares of its common stock to three employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

STERIS plc announced that the Company will distribute a quarterly interim dividend of $0.47 per share.

Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, reported financial results for the fourth quarter and year ended December 31, 2022.

Zentalis™ Pharmaceuticals, Inc. announced that on February 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 12,500 shares of the Company’s common stock to one newly hired employee.